Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Molecular and Clinical Oncology|March 24, 2015
A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapyEriko Takatori, Tadahiro Shoji, Yuki Miura, et al.
Anticancer Research|February 28, 2023
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective StudyMarina Abe, Tadahiro Shoji, Yohei Chiba, et al.
Oncology Letters|September 12, 2012
Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancerTadahiro Shoji, Eriko Takatori, Shinya Hatayama, et al.
Healthcare (Basel, Switzerland)|September 25, 2019
A New Therapeutic Strategy for Recurrent Ovarian Cancer-Bevacizumab beyond Progressive DiseaseTadahiro Shoji, Hisashi Eto, Takanori Sato, et al.
Japanese Journal of Clinical Oncology|January 22, 2024
A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification systemYohei Chiba, Masahiro Kagabu, Mitsumasa Osakabe, et al.
International Journal of Clinical Oncology|January 15, 2025
Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitorsAmi Jo, Tadahiro Shoji, Haruka Otsuka, et al.
Cancers|July 27, 2024
Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian CancerSho Sato, Tadahiro Shoji, Ami Jo, et al.
Cancers|May 13, 2026
Comparative Effectiveness of Bevacizumab and Olaparib Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Real-World Study with Exploratory Evaluation of Dose ReductionShunsuke Tatsuki, Tadahiro Shoji, Ami Jo, et al.
Cancer Science|October 30, 2021
Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023Tadahiro Shoji, Takayuki Enomoto, Masakazu Abe, et al.
The Tohoku Journal of Experimental Medicine|January 26, 2011
Identifying prognostic factors in Japanese women with pseudomyxoma peritonei: a retrospective clinico-pathological study of the Tohoku Gynecologic Cancer UnitTakanobu Kojimahara, Kenji Nakahara, Tadahiro Shoji, et al.
Pageof 9